

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

IN RE: VALSARTAN PRODUCTS LIABILITY
LITIGATION

MDL No. 2875

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO -1)

On February 14, 2019, the Panel transferred 5 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* F.Supp.3d (J.P.M.L. 2019). Since that time, no additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Robert B. Kugler.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Kugler.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of February 14, 2019, and, with the consent of that court, assigned to the Honorable Robert B. Kugler.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.


Feb 25, 2019

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:



Jeffery N. Lüthi
Clerk of the Panel

I HEREBY CERTIFY that the above and foregoing is a true and correct copy of the original on file in my office.
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
WILLIAM T. WALSH, CLERK
By 

**IN RE: VALSARTAN PRODUCTS LIABILITY
LITIGATION**

MDL No. 2875

SCHEDULE CTO-1 – TAG-ALONG ACTIONS

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	<u>CASE CAPTION</u>
ALABAMA NORTHERN			
ALN	5	19-00150	Sen v. Zhejiang Huahai Pharmaceutical Co LTD et al
ARKANSAS WESTERN			
ARW	2	19-02017	Selph v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
CALIFORNIA CENTRAL			
CAC	8	19-00180	Daniel Winiecki v. Zhejiang Huahai Pharmaceutical Co., LTD. et al
CALIFORNIA EASTERN			
CAE	1	19-00212	Avedikian v. Zhejiang Huahai Pharmaceutical Co., Ltd et al
CALIFORNIA NORTHERN			
CAN	5	19-00253	Guiton v. Zhejiang Huahai Pharmaceutical Co., Ltd et al
FLORIDA MIDDLE			
FLM	2	18-00710	Molinaro v. Prinston Pharmaceutical Inc. et al
FLORIDA NORTHERN			
FLN	4	19-00023	BARBER v. ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD et al
FLORIDA SOUTHERN			
FLS	1	18-25260	MSP Recovery Claims, Series LLC v. Huahai US Inc. et al
GEORGIA NORTHERN			

GAN	1	19-00475	Martey v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
INDIANA SOUTHERN			
INS	1	19-00279	BAKER v. MYLAN INC. et al
INS	4	19-00022	WILLIAMS v. ZHEJIANG HUAHAI PHARMACEUTICALS CO., LTD. et al
LOUISIANA EASTERN			
LAE	2	19-00078	Slavich v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
LAE	2	19-00322	Kleinman v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
LOUISIANA WESTERN			
LAW	6	18-01497	Gremillion v. Zhejiang Huahai Pharmaceutical Co Ltd et al
MASSACHUSETTS			
MA	1	18-12339	Longwell v. Camber Pharmaceuticals, Inc. et al
MA	1	19-10074	Barboza et al v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
MA	3	19-30014	Williams v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
MINNESOTA			
MN	0	19-00091	Tack et al v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al
NEW YORK EASTERN			
NYE	2	18-06916	Cacaccio v. Mylan Pharmaceuticals, Inc. et al
NYE	2	19-00332	Nelson v. Teva Pharmaceutical Industries, Ltd. et al
OHIO NORTHERN			
OHN	3	19-00233	Pollock v. Zhejiang Huahai Pharmaceutical Co., Ltd et al
PENNSYLVANIA WESTERN			
PAW	2	19-00046	RODICH-ANNESE v. SOLO HEALTHCARE U.S., LLC et al
TENNESSEE EASTERN			
TNE	3	19-00040	Holland et al v. Zhejiang Huahai Pharmaceutical Co., Ltd. et al (JRG3)